Clinical Trials Browser

Interventional × Pathologic Complete Response × relugolix × Clear all

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual